The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | The impact of ethnicity on biomarker-based staging in AL amyloidosis
Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses the impact of ethnicity on the staging and outcomes of patients with light chain (AL) amyloidosis. A retrospective analysis conducted in the United Kingdom found that different ethnicities exhibited different levels of deprivation, as measured by the Index of Multiple Deprivation (IMD), and that patients from ethnic minorities had significantly lower levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a critical biomarker used in the staging of the disease. However, Dr Khwaja highlights that no difference in overall survival (OS) was observed between white patients and those of other ethnicities. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
